PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAlfacalcidol
Alfacalcidol
Alfacalcidol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
aranespBiologic Licensing Application2024-05-21
florafol fe pediatric 0.25 mg/ml multivitamin and fluoride liquid dropsunapproved drug other2023-12-22
florafol pediatric 0.25 mg/ml multivitamin and fluoride liquid dropsunapproved drug other2023-12-22
pulmozymeBiologic Licensing Application2024-07-09
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A11: Vitamins
— A11C: Vitamin a and d, incl. combinations of the two
— A11CC: Vitamin d and analogues
— A11CC03: Alfacalcidol
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB06: Alendronic acid and alfacalcidol, sequential
HCPCS
No data
Clinical
Clinical Trials
1087 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10241281238
LeukemiaD007938—C95817171—38
HepatitisD006505HP_0012115K75.9313107536
Hepatitis aD006506EFO_0007305B1521397433
Kidney diseasesD007674EFO_0003086N0825712631
SyndromeD013577——71541427
NeoplasmsD009369—C80131041127
Hepatitis cD006526—B19.221076225
Postoperative painD010149—G89.1823271325
GlaucomaD005901EFO_0000516H4013511424
Show 237 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4111—750
Precursor cell lymphoblastic leukemia-lymphomaD054198——41314——28
Lymphoid leukemiaD007945—C9131312——25
Covid-19D000086382——285—417
CarcinomaD002277—C80.010101—117
MelanomaD008545——753—214
AnemiaD000740HP_0001903D64.9241—512
InflammationD007249MP_0001845—123—711
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9311—610
Myeloid leukemiaD007951—C92542——9
Show 160 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376—75———9
Non-small-cell lung carcinomaD002289——57———8
Myelodysplastic syndromesD009190—D4645———7
Inflammatory bowel diseasesD015212EFO_0003767—11——67
Ovarian neoplasmsD010051EFO_0003893C5664———7
AdenocarcinomaD000230——34——26
Parkinson diseaseD010300EFO_0002508G2013——26
Ulcerative colitisD003093EFO_0000729K5113——36
PneumoniaD011014EFO_0003106—12——36
Liver neoplasmsD008113EFO_1001513C22.032——26
Show 183 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599——6————6
Obstructive lung diseasesD008173HP_0006536—2———35
Drug interactionsD004347——4————4
PresbyopiaD011305—H52.43————3
PregnancyD011247EFO_0002950Z33.11———23
Pulmonary arterial hypertensionD000081029——1———12
Liver failureD017093HP_0001399K72.91———12
Hepatic insufficiencyD048550——1———12
Mood disordersD019964EFO_0004247F30-F391———12
HyperemiaD006940EFO_0003822—2————2
Show 76 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intestinal diseasesD007410HP_0002242K63.9————77
Chronic painD059350HP_0012532—————77
Peripheral nervous system diseasesD010523HP_0009830G64————33
NeuralgiaD009437EFO_0009430—————33
Nociceptive painD059226——————33
Musculoskeletal diseasesD009140——————33
Bone fracturesD050723EFO_0003931T14.8————22
MyalgiaD063806HP_0003326M79.1————22
OsteomalaciaD010018EFO_1002027M83————22
Deep sedationD054810——————22
Show 155 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlfacalcidol
INNalfacalcidol
Description
Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a member of D3 vitamins, a seco-cholestane, a hydroxycalciol and a diol. It is functionally related to a calciol.
Classification
Small molecule
Drug classvitamin D analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
Identifiers
PDB—
CAS-ID41294-56-8
RxCUI—
ChEMBL IDCHEMBL1601669
ChEBI ID31186
PubChem CID5282181
DrugBankDB01436
UNII IDURQ2517572 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,359 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aranesp
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,092 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use